| Jonathan Paul Musco, MD | |
|
1 Hospital Dr, Columbia, MO 65212-0001 | |
| (573) 882-1026 | |
| (573) 884-4487 |
| Full Name | Jonathan Paul Musco |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 17 Years |
| Location | 1 Hospital Dr, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245420116 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Physicians Regional Medical Center - Pine Ridge | Naples, FL | Hospital |
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| The Carle Foundation Hospital | Urbana, IL | Hospital |
| Cox Medical Centers | Springfield, MO | Hospital |
| York Hospital | York, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Specialists In Medical Imaging Sc | 2163733544 | 201 |
| Virtual Radiologic Professionals Llc | 4981608817 | 355 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
| Fred Smeltzer Md And Associates Inc | 8921078304 | 44 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Fred Smeltzer Md & Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639122286 PECOS PAC ID: 8921078304 Enrollment ID: O20040731000250 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Virtual Radiologic Professionals Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932342029 PECOS PAC ID: 4981608817 Enrollment ID: O20061207000322 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Specialists In Medical Imaging Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841687951 PECOS PAC ID: 2163733544 Enrollment ID: O20151124000342 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20211011000288 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Ti Tms And Behavioral Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013634328 PECOS PAC ID: 0143699959 Enrollment ID: O20221216000827 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Palm Desert Radiology Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124079868 PECOS PAC ID: 0749173789 Enrollment ID: O20230117001602 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619221686 PECOS PAC ID: 8224282926 Enrollment ID: O20230302000746 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Paul Musco, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | Jonathan Paul Musco, MD 1 Hospital Dr, Columbia, MO 65212-0001 Ph: (573) 882-1026 |
News Archive
Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
The need to enhance healthcare delivery is driving the market for IT professional services in Europe. Adoption levels are, however, being hampered by budget cuts and end user reluctance to invest in such services. These trends have triggered several changes in the market, including consolidation and the adoption of inorganic growth models.
› Verified 2 days ago
Desiree Maria Ferdinandi, Radiology Medicare: Medicare Enrolled Practice Location: One Hospital Dr, Columbia, MO 65212 Phone: 573-884-7770 Fax: 573-882-9876 | |
Dr. Neal R Meyer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 311 N Keene St, Columbia, MO 65201 Phone: 573-442-1788 Fax: 573-442-1789 | |
Dr. Joshua Morrell, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1 Hospital Dr # Dc10m292, Department Of Radiology, School Of Medicine, Columbia, MO 65212 Phone: 701-391-3685 | |
Dr. Ayesha Nasrullah, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: One Hospital Dr, Columbia, MO 65212 Phone: 573-884-7770 Fax: 573-882-9876 | |
Hugh J Murrell, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1705 E Broadway, Suite 100, Columbia, MO 65201 Phone: 573-874-7800 Fax: 573-443-3627 | |
Mustafa Al-sabbagh, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-882-1026 Fax: 573-884-4487 | |
Alex Loiland Pederson, DO Radiology Medicare: Medicare Enrolled Practice Location: One Hospital Dr, Columbia, MO 65212 Phone: 573-884-4082 Fax: 573-884-6661 |